| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Although previous clinical study showed significant effect of trastuzumab for HER2 overexpressed advanced oesophago-gastric adenocarcinoma, the response rate was less than 50%. This study aimed to identify a predictive biomarker of trastuzumab resistance.
In our study, PTEN loss is relatively frequent in HER2 overexpressed gastric cancer patients. PTEN loss might be a potential biomarker to select the HER2 overexpressed oesophago-gastric cancer patients who are less sensitive to the trastuzumab-based chemotherapy.
|
